Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor. OBJECTIVE To determine whether ambrisentan, an ETA receptor-selective antagonist, reduces the rate of IPF progression. DESIGN Randomized, double-blind, placebo-controlled, event-driven trial. (ClinicalTrials.gov: NCT00768300). SETTING Academic and private hospitals. PARTICIPANTS Patients with IPF aged 40 to 80 years with minimal or no honeycombing on high-resolution computed tomography scans. INTERVENTION Ambrisentan, 10 mg/d, or placebo. MEASUREMENTS Time to disease progression, defined as death, respiratory hospitalization, or a categorical decrease in lung function. RESULTS The study was terminated after enrollment of 492 patients (75% of intended enrollment; mean duration of exposure to study medication, 34.7 weeks) because an interim analysis indicated a low likelihood of showing efficacy for the end point by the scheduled end of the study. Ambrisentan-treated patients were more likely to meet the prespecified criteria for disease progression (90 [27.4%] vs. 28 [17.2%] patients; P = 0.010; hazard ratio, 1.74 [95% CI, 1.14 to 2.66]). Lung function decline was seen in 55 (16.7%) ambrisentan-treated patients and 19 (11.7%) placebo-treated patients (P = 0.109). Respiratory hospitalizations were seen in 44 (13.4%) and 9 (5.5%) patients in the ambrisentan and placebo groups, respectively (P = 0.007). Twenty-six (7.9%) patients who received ambrisentan and 6 (3.7%) who received placebo died (P = 0.100). Thirty-two (10%) ambrisentan-treated patients and 16 (10%) placebo-treated patients had pulmonary hypertension at baseline, and analysis stratified by the presence of pulmonary hypertension revealed similar results for the primary end point. LIMITATION The study was terminated early. CONCLUSION Ambrisentan was not effective in treating IPF and may be associated with an increased risk for disease progression and respiratory hospitalizations. PRIMARY FUNDING SOURCE Gilead Sciences.

[1]  H. Collard,et al.  Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan , 2013, Annals of Internal Medicine.

[2]  G. Raghu,et al.  Efficacy And Safety Of Macitentan In Idiopathic Pulmonary Fibrosis: Results Of A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial , 2012, ATS 2012.

[3]  R. Beyer,et al.  Effect Of EndothelinA (ETA) And EndothelinA/B (ETA/B) Receptor Antagonists On Gene Expression In Lungs With Established Fibrosis From A Mouse Pulmonary Fibrosis Model , 2011, Asian Test Symposium.

[4]  H. Ghofrani,et al.  Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[5]  F. Torres,et al.  Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension , 2009, Expert opinion on pharmacotherapy.

[6]  D. Badesch,et al.  ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. , 2009, Cardiovascular therapeutics.

[7]  W. Kirch,et al.  Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? , 2008, European heart journal.

[8]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[9]  A. Borczuk,et al.  Pulmonary hypertension in idiopathic pulmonary fibrosis. , 2007, Chest.

[10]  P. Shaul,et al.  Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. , 2007, American journal of respiratory cell and molecular biology.

[11]  S. Nathan,et al.  Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. , 2007, American journal of respiratory and critical care medicine.

[12]  W. Seeger,et al.  Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study , 2007, European Respiratory Journal.

[13]  M. Mishima,et al.  Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. , 2007, Chest.

[14]  U. Galderisi,et al.  Endothelin‐1 induces proliferation of human lung fibroblasts and IL‐11 secretion through an ETA receptor‐dependent activation of map kinases , 2005, Journal of cellular biochemistry.

[15]  E. Davis.  The Health Care Corporation of St John's: the first five years of regionalization and restructuring , 2005, Journal of health services research & policy.

[16]  J. Lachin.  A review of methods for futility stopping based on conditional power , 2005, Statistics in medicine.

[17]  Yunliang Chen,et al.  Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. , 2004, Molecular biology of the cell.

[18]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.

[19]  C. Smee,et al.  United Kingdom , 2000, International Journal of Pharmaceutical Medicine.

[20]  R. Michel,et al.  Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. , 1997, American journal of respiratory and critical care medicine.

[21]  L. Fasano,et al.  Endothelin-1 in idiopathic pulmonary fibrosis. , 1995, Journal of clinical pathology.

[22]  O. Hilberg,et al.  Idiopathic Pulmonary Fibrosis - Diagnosis and Treatment , 2014 .

[23]  M. L. R. D. Christenson,et al.  An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management , 2012 .

[24]  J. Behr.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[25]  D. Lynch,et al.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[26]  D. Abraham,et al.  Endothelin in pulmonary fibrosis. , 2011, American journal of respiratory cell and molecular biology.

[27]  G. Raghu,et al.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.